# Characterizing the Use of Ofatumumab in a Real World Setting

> **NCT05090033** · — · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 103 (actual)

## Conditions studied

- Relapsing Multiple Sclerosis

## Interventions

- **OTHER:** ofatumumab

## Key facts

- **NCT ID:** NCT05090033
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-12-08
- **Primary completion:** 2026-02-06
- **Final completion:** 2026-02-06
- **Target enrollment:** 103 (ACTUAL)
- **Last updated:** 2026-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05090033

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05090033, "Characterizing the Use of Ofatumumab in a Real World Setting". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05090033. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*